Podcasts Health & Fitness Medicine Oncology Times - OncTimes Talk ASCO 2022 Small Bytes Episode 3: Dr. Marla Lipsyc-Sharf on Personalized ctDNA Testing in Late, HR+, HER2-Negative Breast Cancer

ASCO 2022 Small Bytes Episode 3: Dr. Marla Lipsyc-Sharf on Personalized ctDNA Testing in Late, HR+, HER2-Negative Breast Cancer

Published: June 21, 2022, 9 p.m.

At the ASCO 2022 Annual Meeting, Oncology Times reporter Peter Goodwin interviewed Marla Lipsyc-Sharf, MD, Medical Oncology Fellow at Dana-Farber Cancer Institute/Mass General Brigham, who reported what she believes is the first data on ctDNA detection in late adjuvant, hormone receptor-positive breast cancer. The research showed ctDNA testing was successful in detecting measurable residual disease (MRD) prior to late clinical metastatic recurrence in women with high-risk, HR-positive, HER2-negative breast cancer (Abstract 103).